Serum Levels of TNF-α, IL-12/23 p40, and IL-17 in Psoriatic Patients with and without Nail Psoriasis: A Cross-Sectional Study

Table 1

Patients’ demographic and clinical characteristics, as well as the serum levels of TNF-, IL-12/23 p40, and IL-17.

Characteristics	Psoriatic patients in total ()	Psoriatic patients with cutaneous and nail lesions ()	Psoriatic patients with only cutaneous lesions ()	value
Gender
Male (%)	22 (57.70)	12 (50.00)	10 (35.72)	0.662
Female (%)	30 (42.30)	12 (50.00)	18 (64.28)
Age (years)
Mean ± SD	43.72 ± 12.44	48.12 ± 9.46	41.21 ± 13.53	0.218
Median (min–max)	44.50 (20.00–62.00)	29.00 (30.00–59.00)	42.00 (20.00–62.00)
Disease duration (years)
Mean ± SD	13.36 ± 9.93	20.12 ± 11.08	9.50 ± 6.99
Median (min–max)	11.50 (1.00–40.00)	30.00 (10.00–40.00)	21.00 (1.00–22.00)
Age at psoriasis onset (years)
Mean ± SD	30.81 ± 14.11	29.25 ± 14.26	31.71 ± 14.48	0.704
Median (min–max)	32.00 (10.00–52.00)	39.00 (10.00–49.00)	42.00 (10.00–52.00)
Family history
Yes (%)	21 (40.40)	9 (37.50)	12 (42.85)	0.889
No (%)	31 (59.60)	15 (62.50)	16 (57.15)
PASI score (0–72)
Mean ± SD	4.63 ± 1.93	5.03 ± 2.15	4.40 ± 1.83	0.475
Median (min–max)	4.40 (2.10–9.00)	6.90 (2.10–9.00)	5.70 (2.20–7.90)
Target NAPSI score (0–8)
Mean ± SD	1.90 ± 2.84	3.70 ± 1.75	0.00	N/A
Median (min–max)	0.00 (0.00–8.00)	4.00 (2.00–8.00)	0.00
TNF- (pg/mL)
Mean ± SD	4.38 ± 1.65	5.40 ± 1.17	3.80 ± 1.63
Median (min–max)	4.16 (1.80–7.29)	3.13 (4.16–7.29)	5.33 (1.80–7.13)
IL-12/23 p40 (pg/mL)
Mean ± SD	79.33 ± 42.88	67.13 ± 32.77	86.30 ± 47.41	0.297
Median (min–max)	59.19 (34.35–185.86)	92.52 (34.35–126.87)	150.68 (35.18–185.86)
IL-17 (pg/mL)
Mean ± SD	4.27 ± 6.21	6.27 ± 9.49	3.13 ± 3.15	0.714
Median (min–max)	2.71 (0.00–28.49)	28.49 (0.00–28.49)	8.59 (0.00–8.59)

Statistically significant; comparing the variables between psoriatic patients with and without nail involvement.